Pioneering study combining the diabetes vaccine Diamyd® with GABA in children with type 1 diabetes approved by the US FDA

Diamyd Medical (Nasdaq Stockholm First North, Ticker: DMYD B) informs that an investigator initiated study combining the diabetes vaccine Diamyd® and GABA in children with new onset type 1 diabetes has been approved by the US Food and Drug Administration. Diamyd Medical and University of Alabama at Birmingham has entered a Clinical Trial Agreement regarding the study, which will be conducted at Children’s of Alabama in Birmingham, USA. The combination has shown promising results in preclinical studies.Principal Investigator for the new GABA and Diamyd® combination study is Kenneth McCormick,